Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
-Medical News
 Blood Safety News
 NHF and Community News
 Industry News
 Travel Advisory

 

 

 
FDA Approves New HIV Drug for Hard-to-Treat Patients
 

The U.S. Food and Drug Administration (FDA) has approved etravirine (brand name INTELENCE™) tablets to treat HIV infection in adults who have been treated unsuccessfully with other antiretroviral therapies. Etravirine, which is distributed by Tibotec Therapeutics, is approved for use in combination with other anti-HIV medications. It belongs to the class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs).

When used with other therapies, NNRTIs can inhibit the replication of HIV in the blood by blocking an enzyme the virus needs to multiply. According to the FDA, approval was based largely on two randomized, double-blind, placebo-controlled trials involving 599 adult patients undergoing 24 weeks of anti-HIV therapy. Both studies showed that a greater number of patients on the etravirine/combination regimen had decreased HIV levels in their blood than those receiving a placebo/combination therapy. 

“This is another significant new product for many HIV-infected patients who are
NNRTI–resistant and whose infections are not responding to currently available medications,” said Debra B. Birnkrant, MD, director of the FDA’s Division of Antiviral Products.

The most common side effects of the drug were nausea and skin rashes. Patients who develop a rash while taking INTELENCE™ should call their physician.

Tibotec Therapeutics, which is based in Bridgewater, NJ, is a division of Ortho Biotech Products, L.P.

Read the FDA release

Source: FDA news release dated January 18, 2008

 

This section of our Web site is sponsored by: